Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...boardmarked
MedaSorb at Biotech Showcase 2010 (Audio_& Slideshow-Presentation)
http://webcastingplayer.corporate-ir.net/player/PlayerHost.aspx?EventId=2674413&StreamId=1420772&TIK=&override=reg
Breakthrough Technology
http://www.newcardio.com/what-we-do-breakthrough-technology.php
The standard 12-lead electrocardiogram (ECG or sometimes called EKG) is a diagnostic recording of cardiac electrical activity over time. The 12-lead ECG is cardiology's most frequently used screening and diagnostic tool. Over 200 million ECGs are obtained in the developed world each year, making it the most commonly performed cardiovascular diagnostic test. The ECG has a central role in screening and diagnosis of acute coronary syndromes (heart attack) and many other common forms of heart disease, and often provides the primary basis for critical therapeutic decisions.
Unknown by many, the standard ECG contains latent information about cardiac electrical activity that in total represents the three dimensional (3D) operation of the heart. However, today's standard 12-lead ECG merely represents that data as a series of 2-dimensional time and voltage readings, which must be synthesized into a 3D model of the heart operation by a clinician. It is very difficult, and in the case of some critical parameters impossible, for humans to perform this 3D synthesis in their mind.
NewCardio has developed a new patented and patent pending technology which can process this standard ECG data, and utilize and present it an easy to read format with additional 3D clinically significant diagnostic information. Importantly, no change in clinician practice of how ECG data is collected. Simply said - NewCardio does not change the standard practice for ECG collection.
The past 40 years have brought us remarkable gains in computational power. This creates an opportunity to extract substantially more diagnostically valuable information from the ECG signal. By continuing to develop appropriate mathematical algorithms and software, NewCardio believes that its proprietary 3D approaches can significantly enhance the ECG's diagnostic utility, reduce its complexity, and improve its ease of use for the medical professional. Results of first medical trials of NewCardio's technology at Harvard University Medical School and elsewhere indicate initial results to be very encouraging.
A Message to You (Shareholder)
http://www.b2i.us/profiles/investor/fullpage.asp?f=1&BzID=1645&to=cp&Nav=0&LangID=1&s=0&ID=8337
Dear Fellow Shareholders,
As we approach the end of a transformational year, we are pleased to report to you that our management and board remain very excited about the opportunities before us. The successful commercialization of our initial product, QTinno™, has validated our platform technology which underlies our entire product portfolio. With this platform we believe that we have the potential to add value to virtually every one of the over ¼ billion ECGs taken annually today. In addition, we took steps to strengthen our balance sheet, despite the challenges within the financial markets, by successfully raising $2.9 million in additional growth capital. Members of our management team and board of directors purchased over half of the offering. This raise, coupled with our $3 million line of credit, is expected to fund our operations through the second half of 2010, by which time QTinno is expected to be generating positive cash flow. And finally, we enter 2010 with a strong team of proven industry leaders and the resources to execute our strategic plan.
This year was one of accomplishments. Most notable was the launch of QTinno, and the many efforts to reinforce our 3-D platform technology should not go unnoticed. To date, we have validated QTinno performance in more than 65,000 ECGs from seven drug safety studies, including four Thorough QT (TQT) studies. In all of these clinical validation studies, QTinno demonstrated accuracy and precision equal to or higher than core lab manual readings, with a consistent ability to detect drug induced QT prolongation induced by the moxifloxacin class of drugs (i.e. the “moxi” profile), as required by the FDA and other drug regulatory bodies.
Building on positive industry attention to cardiac safety and our increasingly robust clinical validation, we officially launched QTinno in August. QTinno provides an automated analysis of cardiac safety in drug development. This launch was enabled by an extensive effort by us to ensure organizational readiness to effectively support the sale, implementation and support of QTinno. As many of our shareholders know, every drug in development must undergo a TQT study to determine cardiac toxicity, and currently these studies involve manual or semi-automated readings by cardiologists.. We believe QTinno will replace this primarily manual process with a fully automated solution which promises higher quality results and a more efficient approach.
With our lead product launched, we continue to make steady progress toward securing revenue-generating studies. Notable commercialization-related achievements include:
A top-five pharmaceutical company named QTinno as the technology that will be used in all of its fully automated TQT studies. This pharmaceutical company evaluated several automated cardiac safety solutions before choosing QTinno.
A Master Services Agreement (MSA) was signed with a top-three Clinical Research Organization (CRO), which will use QTinno as their technology in fully automated Phase I TQT studies delivered by their centralized ECG core lab. We expect to collaborate on the first fully automated study in the near future and anticipate the customer will increasingly deliver fully automated studies with QTinno.
Another top-five CRO also signed an MSA with us, licensing QTinno in all TQT studies where fully automated readings are obtained. QTinno will enable them to eliminate the need to utilize ECG core labs for TQT studies delivered by their Phase I units. Ultimately, QTinno will provide the CRO with incremental revenue opportunities by capturing fees that were previously outsourced to ECG core labs.
Dedicated Phase I, an innovative provider of clinical research services signed an MSA with us, licensing our QTinno software solution in all TQT studies where fully automated readings are obtained.
We expect these initial commercial successes to be followed by additional MSAs with leading CRO’s, ECG core labs, Phase I units and potentially some pharmaceutical sponsors who currently perform TQT studies internally. This increased market presence will provide increasing access to the pharmaceutical companies that need to conduct TQT studies on all of their compounds. We anticipate that our first revenue generating studies will be in place in the near term.
Scientific validation coupled with the growing interest by FDA and industry to embrace an automated solution is the other cornerstone to success. In this regard, to support our 3-D platform technology and our lead product, our senior leadership has presented at a wide range of high profile industry events during the last year:
Dr. Ihor Gussak chaired the automated cardiac safety solution segment of the Cardiac Safety Vendor Workshop in London. The segment featured a Who’s Who in the cardiac safety industry focusing on the market adoption of the automated solution. Here, FDA representatives reinforced their support of the use of automated solutions in TQT studies.
Dr. Sam George, our Senior Medical Consultant, joined a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in October. At this meeting, we presented the results from our clinical validation studies clearly showing the superior quality of the data processed by QTinno. In addition, we also demonstrated how validation efforts with QTinno uncovered issues with data processed by the semi-automatic methodology practiced by ECG central core labs, bringing into question the accuracy of the methodology currently considered the standard by the core labs.
We presented two abstracts and discussed new clinical data from analytical and clinical applications of our proprietary platform technology at The Heart Rhythm Society (HRS) 30th Annual Scientific Sessions.
At the DIA Cardiovascular Safety and QT/Arrhythmia Assessment in Drug Development - Optimizing Drug Development Conference, co-sponsored by the FDA and the HRS, we presented our technology and clinical validation results along with our primary automatic solution competitors, and the audience reaction clearly indicated that our results were superior.
These presentations and industry events help increase awareness of our 3-D platform technology and our product offerings. This growing interest has included the opportunity to present QTinno to the FDA, who viewed both the technology and our clinical validation results favorably as they indicated they would accept data processed by QTinno in a prospective TQT study for review. In addition to QTinno, we are excited about the opportunities for our platform technology beyond drug development. We are making progress in our efforts to develop CardioBip™ and Visual3Dx™. We are currently exploring strategic opportunities to include product licensing and, or co-development relationships that would align our resources with large global organizations to accelerate further development and marketing of these exciting platform products. Relationships such as these would accelerate revenue generation and create upside potential to our current plan.
CardioBip is a wireless medical device providing information equivalent to a full 12-lead ECG machine. CardioBip’s target market is outpatient populations with higher risk for, or with diagnosed, cardiovascular disease. The prototype of CardioBip is a trans-telephonic system comprised of a mobile ECG recording and transmitting device and a diagnostic center which receives, processes and analyzes the data. CardioBip allows a patient to record ECG data with a mobile recorder by easily self-placing it on the patient’s chest. We believe there is emerging opportunity in remote patient monitoring, especially using a wireless device. Recent comments by the FDA, and current trials, indicate that this is a particular area of focus with increasing investment and regulatory attention. Atrial fibrillation (AF) monitoring is a new, yet potentially lucrative, opportunity for CardioBip. AF, the most common type of arrhythmia, is a rapid uncoordinated generation of electrical impulses by the atrial chambers of the heart. In the US alone, more than two million patients are estimated to have AF. AF is commonly treated by use of anti-arrhythmic drugs, but the effectiveness of this therapy is limited and the resulting side effects may not be well tolerated. In order to assess the clinical progression of patients that undergo AF treatment procedures, the HRS Atrial Fibrillation Task Force recommends that AF patients be monitored, using an event monitor, for recurrent arrhythmias for up to two years. This new trend in AF remote patient monitoring opens up an opportunity for deployment of devices such as CardioBip.
Visual3Dx provides a comprehensive method to assess cardiac electrical activity in time and space. This product applies our 3-D algorithms in order to significantly enhance the value of a standard ECG, targeting the urgent care market initially. The product extracts additional information from standard 12-lead ECG signals by incorporating algorithms for real-time vectorial analysis and normalization tools to ensure accurate representation of all heart regions. This enables Visual3Dx to assess potentially fatal diseases and conditions, including acute coronary syndrome (ACS), with far greater accuracy than possible by standard ECG. Clinical results to date indicate there can be a 20% improvement in sensitivity. This demonstrates a substantial potential for improvement in accuracy in diagnosis of acute MI.
For 2010, our goals are to build upon our R&D and clinical validation successes that are driving the adoption of QTinno, in order to generate revenues sufficient to achieve profitability by the end of the year. We continue to develop additional relationships with sponsors, CRO’s, clinical pharmacology units and ECG core labs to achieve this goal. The industry is moving in the direction of automated studies, and our solutions provide the ideal method to achieve their objectives. We also plan to ramp up our new product development in conjunction with the appropriate strategic partners. We will be investing in additional R&D to advance Visual3Dx and CardioBip as we pursue these relationships, some of which may result in incremental revenue opportunities as early as 2010. We are particularly excited about the opportunities for the wireless CardioBip platform with the increasing industry focus on AF.
In summary, 2009 was a milestone year and 2010 brings a new focus – wireless – as we become a growing commercial enterprise. We have developed a disruptive technology that is ideally suited for the direction the drug industry is moving. We have received positive reactions from regulators and specifically the FDA, and are receiving an encouraging reaction from pharmaceutical companies. We have an exceptionally deep and talented team in place, and we are well-positioned for success in 2010 and beyond. Our board and management team remain excited about our opportunities and potential, and we trust you share this enthusiasm.
Sincerely,
Branislav Vajdic, Ph.D.
CEO
Vincent W. Renz, Jr.
President and COO
...some DD ?? well -
http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1645&GoTopage=&Category=1202
Jul 30, 2009
Top-Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution
Aug 27, 2009
NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization
Sep 09, 2009
NewCardio Announces Master Services Agreement with Top Five CRO
Jan 14, 2010
NewCardio Awarded Key U.S. Patent for CardioBip
...
...i like it - bashers arrived !
"sources confirmed to BioMedReports on Thursday afternoon that discussions are definitely underway" -
WHAT SOURCES? Until they release the names of their sources and they can be confirmed - this is nothing but rumormongering.
This is pumping at its utmost. This publication has a vested interest pumping the pps of NWCI as they have a position in the company. Isn't this illegal?
Please do your own DD before you put your funds to risk.
This post is in no way intended to dissuade or persuade anyone from opening or closing a position in any equity.
KERX
Healthcare Conference Updates ...
Written by Mike Havrilla
Friday, 15 January 2010 09:09
http://biomedreports.com/articles/most-popular/24879-healthcare-conference-updates-auxl-ctic-cytx-kerx.html
Below are some updates and developments from the past week, which I spent in San Francisco for the OneMed, JP Morgan, and other healthcare conferences.
I had the opportunity to meet with the CEO (Ron Bentsur) and CFO (James Oliviero) of Keryx Biopharma (NASDAQ: KERX) on Wednesday and was impressed with the Company's focused strategy and upcoming milestones for 2010 and beyond. As outlined in my overview article last week, I have purchased shares of KERX over the past week on weakness at a slightly higher price range ($2.70-2.75) than I originally projected.
Given the Company's history of in-licensing compounds for development and robust cash position, I inquired if anything was on the horizon in this regard. However, for the near to intermediate term, Keryx plans to remain focused on utilizing its resources (cash / personnel) to get the Phase 3 trials well established before considering any new acquisitions, which is a good strategy given that Keryx is well-funded but still a small-cap drug developer that needs to remain focused.
Approximately $10-11 million is the estimated cost to fund both the short and long-term Phase 3 studies of Zerenex while perifosine has estimated funding of $12 million each to fund the Phase 3 studies for multiple myeloma (ongoing) and colorectal cancer (pending), with an estimate of $25,000-$30,000 per patient to fund the Phase 3 cancer trials. Below is a summary of additional details for upcoming catalysts and milestones for Keryx over this year and beyond that were not included in my overview article last week.
During 2010, Keryx expects to report updated data from its Phase 2 colon cancer study, conduct / update additional earlier stage Phase I/II studies, finalize late-stage trial protocol for colon cancer study, and begin additional late-stage studies for colon cancer in addition to the pending pivotal Phase 3 study of perifosine under a SPA agreement with FDA for multiple myeloma. KERX expects to provide an update on Phase 2 colon cancer survival and other data for perifosine next weekend at GI-ASCO 2010 (Jan. 22-24) as it prepares to begin a pivotal Phase 3 trial of perifosine in colon cancer patients with a Special Protocol Assessment (SPA) with the FDA possible for this indication within the next 2-3 months (i.e. mid-April 2010).
The ongoing Zerenex Phase 2 study in Japan by JT Torii is near completion and Keryx expects the Phase 3 trial to begin during 2H10, which will trigger a development milestone payment that is in the mid single-digit million dollar range. An additional $15 million milestone is possible upon regulatory approval in Japan, with approximately $55 million in remaining milestone payments based on the achievement of sales targets upon commercialization.
Zerenex represents a niche market opportunity within well understood / established class of drugs (phosphate binders) that has a key differentiation of being iron-based compared to existing treatments such as PhosLo, Fosrenol, and Renagel/Renvela. Zerenex is expected to offer an improved safety profile / patient acceptance with reduced GI / bloating side effects and approximately 50% less dosing burden (i.e. taking less pills less often) compared to existing phosphate binders.
In addition, a major secondary endpoint being evaluated is the potential ability of Zerenex to decrease the need for IV-iron and blood cell stimulators (EPO agents such as Epogen and Aranesp) since it is iron based and expected to result in long-term accumulation of the mineral. This may result in a first-line phosphate binder indication (with a goal of capturing 20-25% market share) for Zerenex and advantages that include safety (there is a pending FDA Advisory Panel to discuss safety issues of EPO drugs) and economic (dialysis bundling payment issues - Zerenx has potential to save dialysis providers money by reducing need for IV-iron or EPO agents).
http://www.finviz.com/quote.ashx?t=KERX&ty=c&ta=0&p=w
Stem Cell Innovations Inc. - Company Report (01.13,2010)
Life Science Analytics
http://reports.finance.yahoo.com/w0?r=44522011:1
?? can we get a <SCLL> annotated Chart ??
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45460118
thanks for your advice!
ax
IBOX updated!
NWCI CEO-Presentation @ OneMedForum (01.12,2010)
14:15 min http://www.ustream.tv/recorded/3936678
Healthcare Conference Updates: KERX
Written by Mike Havrilla
Friday, 15 January 2010 09:09
http://biomedreports.com/articles/most-popular/24879-healthcare-conference-updates-auxl-ctic-cytx-kerx.html
Below are some updates and developments from the past week, which I spent in San Francisco for the OneMed, JP Morgan, and other healthcare conferences.
I had the opportunity to meet with the CEO (Ron Bentsur) and CFO (James Oliviero) of Keryx Biopharma (NASDAQ: KERX) on Wednesday and was impressed with the Company's focused strategy and upcoming milestones for 2010 and beyond. As outlined in my overview article last week, I have purchased shares of KERX over the past week on weakness at a slightly higher price range ($2.70-2.75) than I originally projected.
Given the Company's history of in-licensing compounds for development and robust cash position, I inquired if anything was on the horizon in this regard. However, for the near to intermediate term, Keryx plans to remain focused on utilizing its resources (cash / personnel) to get the Phase 3 trials well established before considering any new acquisitions, which is a good strategy given that Keryx is well-funded but still a small-cap drug developer that needs to remain focused.
Approximately $10-11 million is the estimated cost to fund both the short and long-term Phase 3 studies of Zerenex while perifosine has estimated funding of $12 million each to fund the Phase 3 studies for multiple myeloma (ongoing) and colorectal cancer (pending), with an estimate of $25,000-$30,000 per patient to fund the Phase 3 cancer trials. Below is a summary of additional details for upcoming catalysts and milestones for Keryx over this year and beyond that were not included in my overview article last week.
During 2010, Keryx expects to report updated data from its Phase 2 colon cancer study, conduct / update additional earlier stage Phase I/II studies, finalize late-stage trial protocol for colon cancer study, and begin additional late-stage studies for colon cancer in addition to the pending pivotal Phase 3 study of perifosine under a SPA agreement with FDA for multiple myeloma. KERX expects to provide an update on Phase 2 colon cancer survival and other data for perifosine next weekend at GI-ASCO 2010 (Jan. 22-24) as it prepares to begin a pivotal Phase 3 trial of perifosine in colon cancer patients with a Special Protocol Assessment (SPA) with the FDA possible for this indication within the next 2-3 months (i.e. mid-April 2010).
The ongoing Zerenex Phase 2 study in Japan by JT Torii is near completion and Keryx expects the Phase 3 trial to begin during 2H10, which will trigger a development milestone payment that is in the mid single-digit million dollar range. An additional $15 million milestone is possible upon regulatory approval in Japan, with approximately $55 million in remaining milestone payments based on the achievement of sales targets upon commercialization.
Zerenex represents a niche market opportunity within well understood / established class of drugs (phosphate binders) that has a key differentiation of being iron-based compared to existing treatments such as PhosLo, Fosrenol, and Renagel/Renvela. Zerenex is expected to offer an improved safety profile / patient acceptance with reduced GI / bloating side effects and approximately 50% less dosing burden (i.e. taking less pills less often) compared to existing phosphate binders.
In addition, a major secondary endpoint being evaluated is the potential ability of Zerenex to decrease the need for IV-iron and blood cell stimulators (EPO agents such as Epogen and Aranesp) since it is iron based and expected to result in long-term accumulation of the mineral. This may result in a first-line phosphate binder indication (with a goal of capturing 20-25% market share) for Zerenex and advantages that include safety (there is a pending FDA Advisory Panel to discuss safety issues of EPO drugs) and economic (dialysis bundling payment issues - Zerenx has potential to save dialysis providers money by reducing need for IV-iron or EPO agents).
Healthcare Conference Updates: KERX
Written by Mike Havrilla
Friday, 15 January 2010 09:09
http://biomedreports.com/articles/most-popular/24879-healthcare-conference-updates-auxl-ctic-cytx-kerx.html
Below are some updates and developments from the past week, which I spent in San Francisco for the OneMed, JP Morgan, and other healthcare conferences.
I had the opportunity to meet with the CEO (Ron Bentsur) and CFO (James Oliviero) of Keryx Biopharma (NASDAQ: KERX) on Wednesday and was impressed with the Company's focused strategy and upcoming milestones for 2010 and beyond. As outlined in my overview article last week, I have purchased shares of KERX over the past week on weakness at a slightly higher price range ($2.70-2.75) than I originally projected.
Given the Company's history of in-licensing compounds for development and robust cash position, I inquired if anything was on the horizon in this regard. However, for the near to intermediate term, Keryx plans to remain focused on utilizing its resources (cash / personnel) to get the Phase 3 trials well established before considering any new acquisitions, which is a good strategy given that Keryx is well-funded but still a small-cap drug developer that needs to remain focused.
Approximately $10-11 million is the estimated cost to fund both the short and long-term Phase 3 studies of Zerenex while perifosine has estimated funding of $12 million each to fund the Phase 3 studies for multiple myeloma (ongoing) and colorectal cancer (pending), with an estimate of $25,000-$30,000 per patient to fund the Phase 3 cancer trials. Below is a summary of additional details for upcoming catalysts and milestones for Keryx over this year and beyond that were not included in my overview article last week.
During 2010, Keryx expects to report updated data from its Phase 2 colon cancer study, conduct / update additional earlier stage Phase I/II studies, finalize late-stage trial protocol for colon cancer study, and begin additional late-stage studies for colon cancer in addition to the pending pivotal Phase 3 study of perifosine under a SPA agreement with FDA for multiple myeloma. KERX expects to provide an update on Phase 2 colon cancer survival and other data for perifosine next weekend at GI-ASCO 2010 (Jan. 22-24) as it prepares to begin a pivotal Phase 3 trial of perifosine in colon cancer patients with a Special Protocol Assessment (SPA) with the FDA possible for this indication within the next 2-3 months (i.e. mid-April 2010).
The ongoing Zerenex Phase 2 study in Japan by JT Torii is near completion and Keryx expects the Phase 3 trial to begin during 2H10, which will trigger a development milestone payment that is in the mid single-digit million dollar range. An additional $15 million milestone is possible upon regulatory approval in Japan, with approximately $55 million in remaining milestone payments based on the achievement of sales targets upon commercialization.
Zerenex represents a niche market opportunity within well understood / established class of drugs (phosphate binders) that has a key differentiation of being iron-based compared to existing treatments such as PhosLo, Fosrenol, and Renagel/Renvela. Zerenex is expected to offer an improved safety profile / patient acceptance with reduced GI / bloating side effects and approximately 50% less dosing burden (i.e. taking less pills less often) compared to existing phosphate binders.
In addition, a major secondary endpoint being evaluated is the potential ability of Zerenex to decrease the need for IV-iron and blood cell stimulators (EPO agents such as Epogen and Aranesp) since it is iron based and expected to result in long-term accumulation of the mineral. This may result in a first-line phosphate binder indication (with a goal of capturing 20-25% market share) for Zerenex and advantages that include safety (there is a pending FDA Advisory Panel to discuss safety issues of EPO drugs) and economic (dialysis bundling payment issues - Zerenx has potential to save dialysis providers money by reducing need for IV-iron or EPO agents).
"Orion Party Bash MLK Day Contest Pick" KERX
Healthcare Conference Updates: AUXL, CTIC, CYTX, KERX
Written by Mike Havrilla
Friday, 15 January 2010 09:09
http://biomedreports.com/articles/most-popular/24879-healthcare-conference-updates-auxl-ctic-cytx-kerx.html
NWCI "Buyout_in_the_Works" After Company is Awarded Key Patent
Written by M.E.Garza
Thursday, 14 January 2010 23:49
http://biomedreports.com/articles/most-popular/24839-nwci-buyout-in-the-works-after-company-gets-key-patent.html
Another buyout rumor is engulfing the biotech sector. This one comes on the heels of Thursday morning's key patent news announcement for small cap, NewCardio (NWCI.OB).
This Silicon Valley based company with a very small share float wanted "very badly" to meet with us for a one-on-one interview session at the OneMedForum conference in San Francico. Suddenly, they dropped off the face of the earth and no one could be reached for comments, much less an interview.
Why? What happened?
On the last day of the conference, rumors began to fly that the company was in deep negotiations for a buy out. After chasing the story for the last 24 hours, and seeing the key patent announcement hit the news wires on Thursday morning, it is my opinion that if the buyout occurs, it will likely send shares of NewCardio somewhere between $10 and $14.
The company has a hot new technology that is shaping up to be not only the next great diagnostics tool in cardiovascular medicine, but could also turn into "the ultimate medical phone app." There is talk about a hardware/software combo that would allow anyone to hold a smart phone-like device up to their chest in order to interpret/communicate the readings directly to a doctor.
Designers of this technology (who come from a tech background designing chips and microprocessors) have figured out that a great number of doctors simply do not know how to interpret heart monitor signals either correctly or accurately. They feel that EKG technology is "under utilized" as a diagnostics tool and see a multi-billion dollar market for their products.
Thursday morning, the company announced news about a key patent (which needed to be in place before the rumored sale) and the news sent shares flying.
If the rumors of the buyout are true, (sources confirmed to BioMedReports on Thursday afternoon that discussions are definitely underway) then shares could easily continue to climb from Thursday's already unusual high trading/volume levels.
According to an upbeat presentation at the OneMedForum in San Francisco earlier this week, NewCardio is said to be entering the commercial phase as a cardiac diagnostic and services company.
The company's proprietary software platform technologies provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development.
More videos and presentations can be found on the company's website: http://www.newcardio.com/what-we-do-presentations.php
Blockbuster(R) Eliminates Final $24 Million Letters of Credit Agreement With Viacom
Date : 01/14/2010 @ 11:00AM
Source : PR Newswire
Stock : Blockbuster, Inc. (BBI)
http://ih.advfn.com/p.php?pid=nmona&article=41110499&symbol=BBI
http://www.shortsqueeze.com/?symbol=bbi&submit=Short+Quote%99
Short Interest (Shares Short)
29,673,800
Days To Cover (Short Interest Ratio)
22.4
Short Percent of Float
24.98 %
Record Date
2010-JanA
?? short interest !
http://www.shortsqueeze.com/?symbol=bbi&submit=Short+Quote%99
Short Interest (Shares Short)
29,673,800
Days To Cover (Short Interest Ratio)
22.4
Short Percent of Float
24.98 %
Record Date
2010-JanA
Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director ...
Date : 01/14/2010 @ 8:30AM
Source : PR Newswire
Stock : Encorium Grp. (MM) (ENCO)
http://ih.advfn.com/p.php?pid=nmona&article=41106911&symbol=ENCO
Announces Results of Stockholder Voting at its Annual Meeting of Stockholders held on January 8, 2010
BERWYN, Pa., Jan. 14 /PRNewswire-FirstCall/ --
Encorium Group, Inc. (NASDAQ:ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has re-appointed Dr. Kai Lindevall as Chief Executive Officer. In addition, the Board of Directors has appointed Shahab Fatheazam, a current director of the Company, as Chairman of the Board of Directors
Dr. Lindevall had previously served as Executive Chairman and President of Europe and Asia from July 2009 until present, Chief Executive Officer of the Company from February 2008 until September 2008 and as President, Europe and Asian Operations from November 2006 until February 2008
Mr. Fatheazam most recently served as Managing Director and head of the U.S. healthcare practice of GCA Savvian, a leading international investment banking advisory firm. Mr. Fatheazam joined GCA Savvian in 2004 from Vector Securities, a premier healthcare specialty firm, where he was a partner. Prior to helping to form Vector Securities, he was co-head of Paine Webber's Lifescience Division. He began his career on Wall Street with Kidder, Peabody & Co, where, in 1980, he became a partner and senior executive in Kidder's international corporate finance unit. Mr. Fatheazam holds a BA and MA from Cambridge University in England and an MBA from Columbia University. Mr. Fatheazam sits on the boards of two biotechnology companies and is a Trustee at Chicago University's Harris School. He is a member of the Economics Club in Chicago
On the appointment of Mr. Fatheazam, Dr. Kai Lindevall commented, "Since his appointment to the Board of Directors in November 2008, Mr. Fatheazam has significantly contributed to the Board and the execution of the Company's business and management. He has a long and successful career in the health care and public company environment and the Board is extremely pleased to have his leadership in building stockholder value."
Mr. Fatheazam stated, "The ever changing world of pharmaceutical testing of future therapeutics and the means of delivering them, make the CRO industry very dynamic and interesting. Encorium has an international experience which plays very well with the needs of the pharmaceutical and biotech industries. It is my goal to always improve and keep apace of the requirements necessary to be an effective player in the field."
The Company also announced today the results of stockholder voting at its Annual Meeting of Stockholders held on January 8, 2010. The Company reported that approximately 70% percent of the outstanding shares were represented either in person or by proxy at the meeting
Encorium stockholders voted to elect all five nominees to the Board of Directors, namely, Shahab Fatheazam, Sari Laitinen, Dr. Kai Lindevall, Petri Manninen, and David Morra to serve until the next annual meeting or until their successors are elected; ratified the appointment of Asher & Company, Ltd. as the Company's independent registered public accountants for the fiscal year ending December 31, 2009; and approved the issuance of 874,126 shares of its common stock issuable under warrant exchange agreements with two private investors, as well as any additional shares underlying the exchange warrants that may be issuable as a result of the anti-dilution provisions set forth in such instruments
In addition, Encorium stockholders approved an amendment to its Certificate of Incorporation, as amended, to affect a reverse stock split of shares of the Company's common stock issued and outstanding at a ratio to be established by our Board of Directors in its discretion of up to one for 10 (but not less than one for three). If the reverse split is affected by our Board of Directors, we can not assure you that that we will be able to comply with the other requirements for continued listing on NASDAQ in order to maintain our listing on the NASDAQ Capital Market. As previously disclosed, on August 25, 2009, the Company received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ had determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1). On October 19, 2009 the Company received a letter from NASDAQ extending to December 8, 2009 the time to regain compliance with Rule 5550(b). NASDAQ will continue to monitor the Company's ongoing compliance with the stockholder's equity requirement and has informed that Company that, if at the time of its next periodic report for the year ending December 31, 2009 the Company does not evidence compliance, the Company may be subject to delisting. Based on the Company's preliminary results for the period ending December 31, 2009 the Company does not believe it will satisfy this requirement. If the Company does not, the Company may request a hearing before the NASDAQ Listing Qualifications Panel. Such request would stay any delisting determination by the NASDAQ Listing Qualifications Staff and the Company's common stock would remain listed on NASDAQ pending a formal determination by the Panel
About Encorium Group, Inc
Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process
This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; and (xiii) uncertainties regarding the availability of additional capital; and (xiv) uncertainties regarding continued listing of our common stock on NASDAQ. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2009 for a more complete discussion of factors which could cause our actual results and financial position to change.
DATASOURCE: Encorium Group, Inc
CONTACT: Phil Calamia, +1-484-686-4759, for Encorium Group, Inc
...Reason for AS-raising:
http://ih.advfn.com/p.php?pid=nmona&cb=1263418489&article=38506674&symbol=NO^SCLL
Because the Company only has 4 billion authorized shares of common stock, of which 1,681,137,312 shares are issued and outstanding, and because $1 million of Ms. Chassman’s convertible notes (or Series 3 Stock) issued by the Company are now convertible into 5 billion shares of its common stock, full conversion of these notes (or shares of Series 3 Stock) also requires that the Company increase the number of shares of common stock it is authorized to issue. Accordingly, the Company is seeking approval of the second Amendment, which will increase the authorized shares of common stock from 4 billion to 20 billion.
################################################################################################
As of June 24, 2009, there were outstanding 1,681,137,312 shares of our common stock...
http://ih.advfn.com/p.php?pid=nmona&cb=1263418489&article=38506674&symbol=NO^SCLL
(As of Jan, 2010), there are currently 2,844,387,312 shares issued and outstanding...
http://ih.advfn.com/p.php?pid=nmona&cb=1263418830&article=41095210&symbol=NO^SCLL
CEL-SCI Corporation Announces 2009 Financial Results / Company Ends Fiscal Year in Strongest Financial Condition Ever; Receives Clean and Unqualified Audit Opinion
13.01.2010 22:20
http://www.finanznachrichten.de/nachrichten-2010-01/15888408-cel-sci-corporation-announces-2009-financial-results-company-ends-fiscal-year-in-strongest-financial-condition-ever-receives-clean-and-unqualified-008.htm
VIENNA, Va., Jan. 13 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) reports financial results for the fiscal year ended September 30, 2009.
CEL-SCI reported an operating loss for fiscal year 2009 of $ (12,100,550) versus an operating loss of $ (9,517,358) in fiscal year 2008. Included in this operating loss in 2009 were non-cash expenditures that added up to approximately $5.5 million. In addition, CEL-SCI also incurred a $28.5 million non-cash loss related to derivative accounting. This loss was primarily a result of the significant increase in the Company's share price. CEL-SCI expects to report a substantial gain related to derivative accounting in the quarter ending December 31, 2009.
The operating loss included research and development (R&D) expenses of $ 6.0 million in fiscal 2009 compared to $4.1 million in fiscal 2008. R&D expenses increased due to higher costs associated with preparing for the Company's upcoming Phase III clinical trial of its cancer drug Multikine®.
Geert Kersten, Chief Executive Officer said, "We concluded fiscal year 2009 in the strongest financial condition ever, with more than $33,550,000 in cash and cash equivalents, allowing us to self-fund our upcoming pivotal Phase III study with our cancer drug Multikine. We are excited that we are in position to move Multikine through the clinic without losing rights to any of the major markets and to continue to develop our L.E.A.P.S.(TM) technology platform in areas such as H1N1 and Rheumatoid Arthritis."
Multikine is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.
In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S. technology platform. This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is currently being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit http://www.cel-sci.com/ .
...
CEL-SCI Corporation Announces 2009 Financial Results / Company Ends Fiscal Year in Strongest Financial Condition Ever; Receives Clean and Unqualified Audit Opinion
13.01.2010 22:20
http://www.finanznachrichten.de/nachrichten-2010-01/15888408-cel-sci-corporation-announces-2009-financial-results-company-ends-fiscal-year-in-strongest-financial-condition-ever-receives-clean-and-unqualified-008.htm
VIENNA, Va., Jan. 13 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) reports financial results for the fiscal year ended September 30, 2009.
CEL-SCI reported an operating loss for fiscal year 2009 of $ (12,100,550) versus an operating loss of $ (9,517,358) in fiscal year 2008. Included in this operating loss in 2009 were non-cash expenditures that added up to approximately $5.5 million. In addition, CEL-SCI also incurred a $28.5 million non-cash loss related to derivative accounting. This loss was primarily a result of the significant increase in the Company's share price. CEL-SCI expects to report a substantial gain related to derivative accounting in the quarter ending December 31, 2009.
The operating loss included research and development (R&D) expenses of $ 6.0 million in fiscal 2009 compared to $4.1 million in fiscal 2008. R&D expenses increased due to higher costs associated with preparing for the Company's upcoming Phase III clinical trial of its cancer drug Multikine®.
Geert Kersten, Chief Executive Officer said, "We concluded fiscal year 2009 in the strongest financial condition ever, with more than $33,550,000 in cash and cash equivalents, allowing us to self-fund our upcoming pivotal Phase III study with our cancer drug Multikine. We are excited that we are in position to move Multikine through the clinic without losing rights to any of the major markets and to continue to develop our L.E.A.P.S.(TM) technology platform in areas such as H1N1 and Rheumatoid Arthritis."
Multikine is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.
In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S. technology platform. This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is currently being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit http://www.cel-sci.com/ .
...
SCLL - Current report filing (8-K)
Date : 01/13/2010 @ 3:00PM
Source : Edgar (US Regulatory)
Stock : - (SCLL)
http://ih.advfn.com/p.php?pid=nmona&cb=1263413430&article=41095210&symbol=NO^SCLL
Stem Cell Innovations, Inc., (SCLL.PK) wishes to update its shareholders on various aspects of the company over the past year.
Our human embryonic germ cell technology has matured substantially. This work was significantly more difficult than originally anticipated but has resulted in a series of interesting and useful observations that will fill in several missing pieces in human stem cell biology. These observations are currently being finalized and assembled into a form suitable for publication in scientific journals. We anticipate the publication of several such scientific papers over the coming year and these advances will enable us to pursue the application of our technology to drug discovery, liver disease and cancer. It is important to note that this technology is completely separate from standard human embryonic stem cells and comprises a unique and valuable intellectual property.
As a result of the shareholder vote that was held in August, the number of authorized shares was expanded to 20 billion. There are currently 2,844,387,312 shares issued and outstanding. The financing by Margie Chassman that was announced in conjunction with the vote has been completed. These funds, along with income from ongoing and new contract research, should enable the Company to put a program in place over the next six to nine months that will enable us to become listed again on the Bulletin Board and become current with our filings. It is important to the Company to be as transparent as possible within the confines of this difficult financial environment and we are working diligently to achieve this.
... income from ongoing and new contract research, should enable the Company to put a program in place over the next six to nine months that will enable us to become listed again on the Bulletin Board and become current with our filings.
http://ih.advfn.com/...4471&article=41095210&symbol=NO%5ESCLL
There are currently 2,844,387,312 shares issued and outstanding.
The financing by Margie Chassman that was announced in conjunction with the vote has been completed.
These funds, along with income from ongoing and new contract research, should enable the Company to put a program in place over the next six to nine months that will enable us to become listed again on the Bulletin Board and become current with our filings.
http://ih.advfn.com/p.php?pid=nmona&cb=1263414471&article=41095210&symbol=NO%5ESCLL
Current report filing (8-K)
Date : 01/13/2010 @ 3:00PM
Source : Edgar (US Regulatory)
Stock : - (SCLL)
http://ih.advfn.com/p.php?pid=nmona&cb=1263413430&article=41095210&symbol=NO^SCLL
Stem Cell Innovations, Inc., (SCLL.PK) wishes to update its shareholders on various aspects of the company over the past year.
Our human embryonic germ cell technology has matured substantially. This work was significantly more difficult than originally anticipated but has resulted in a series of interesting and useful observations that will fill in several missing pieces in human stem cell biology. These observations are currently being finalized and assembled into a form suitable for publication in scientific journals. We anticipate the publication of several such scientific papers over the coming year and these advances will enable us to pursue the application of our technology to drug discovery, liver disease and cancer. It is important to note that this technology is completely separate from standard human embryonic stem cells and comprises a unique and valuable intellectual property.
As a result of the shareholder vote that was held in August, the number of authorized shares was expanded to 20 billion. There are currently 2,844,387,312 shares issued and outstanding. The financing by Margie Chassman that was announced in conjunction with the vote has been completed. These funds, along with income from ongoing and new contract research, should enable the Company to put a program in place over the next six to nine months that will enable us to become listed again on the Bulletin Board and become current with our filings. It is important to the Company to be as transparent as possible within the confines of this difficult financial environment and we are working diligently to achieve this.
This update contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as “expects”, “intends”, “believes”, “may”, “will” and “anticipates” to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company’s periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.
If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.
Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
11.01.2010 07:31
http://www.finanznachrichten.de/nachrichten-2010-01/15858611-cell-therapeutics-inc-cti-to-present-at-the-28th-annual-jp-morgan-healthcare-conference-008.htm
Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
11.01.2010 07:31
http://www.finanznachrichten.de/nachrichten-2010-01/15858611-cell-therapeutics-inc-cti-to-present-at-the-28th-annual-jp-morgan-healthcare-conference-008.htm
SEATTLE, Jan. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 28th Annual JP Morgan Healthcare Conference in San Francisco. The conference will be held January 11-14, 2010, at the Westin St. Francis. CTI will present on Thursday, January 14, 2010, 2:00 PM Pacific Time. The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at http://www.celltherapeutics.com/.
28th Annual JP Morgan Healthcare Conference CTI Presentation: Thursday, January 14, 2010 2:00 PM Pacific /5:00 PM Eastern/11:00 PM Central European Audio webcast with slides at http://www.celltherapeutics.com/ Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 F: 206.272.4434 E: deramian@ctiseattle.com http://www.celltherapeutics.com/press_room Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: invest@ctiseattle.com http://www.celltherapeutics.com/investors
Cell Therapeutics, Inc.
CONTACT: media, Dan Eramian of Cell Therapeutics, Inc., +1-206-272-4343,
cell, +1-206-854-1200, fax, +1-206-272-4434, deramian@ctiseattle.com, or,
investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch Logan, +1-206-272-4347,
both of Cell Therapeutics, Inc., fax, +1-206-272-4434, invest@ctiseattle.com
Web Site: http://www.celltherapeutics.com/
OT: Thousands feared dead in Haitian quake disaster
U.S. carriers cancel flights to Port-au-Prince
Jan. 13, 2010, 9:02 a.m. EST
http://www.marketwatch.com/story/thousands-feared-dead-in-haiti-quake-2010-01-13
NEW YORK (MarketWatch) - Aid groups from the U.S. and around the world on Wednesday mobilized efforts to Haiti, where the worst earthquake in 200 years raised fears of a death toll well into the thousands, according to reports Wednesday.
ProLogis to Participate in the Deutsche Bank 2010 Real Estate Outlook Conference
Date : 01/12/2010 @ 5:15PM
Source : PR Newswire
Stock : Prologis (PLD)
http://ih.advfn.com/p.php?pid=nmona&article=41078381&symbol=PLD
ProLogis to Participate in the Deutsche Bank 2010 Real Estate Outlook Conference
DENVER, Jan. 12 /PRNewswire-FirstCall/ --
ProLogis (NYSE:PLD), a leading global provider of distribution facilities, announced today that it will participate in the Deutsche Bank 2010 Real Estate Outlook Conference being held at The Pierre Hotel in New York City on January 13, 2010. Bill Sullivan, chief financial officer for ProLogis, will participate in an industrial panel at 3:00pm Eastern Time
You may listen to the webcast of the panel by going to ProLogis' website at http://ir.prologis.com/ and clicking on the link provided under "Presentations & Webcasts." At this location, you will also find the company's presentation being used in meetings with investors starting at 8:00am Eastern Time on January 13, 2010. The presentation covers topics such as property fund financing activity, land monetization and future earnings upside
About ProLogis
ProLogis is a leading global provider of distribution facilities, with more than 475 million square feet of industrial space owned and managed (44 million square meters) in markets across North America, Europe and Asia. The company leases its industrial facilities to more than 4,500 customers, including manufacturers, retailers, transportation companies, third-party logistics providers and other enterprises with large-scale distribution needs. For additional information about the company, go to http://www.prologis.com/.
DATASOURCE: ProLogis
CONTACT: Robbin Lee of ProLogis, +1-303-567-5690,
Web Site: http://www.prologis.com/